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ABSTRACT
Introduction: Schistosomiasis is an infectious parasitic disease caused by trematodes 
of the genus Schistosoma, which threatens at least 258 million people worldwide and its 
control is dependent on a single drug, praziquantel. The aim of this study was to evaluate 
the anti-Schistosoma mansoni activity in vitro of novel imidazolidine derivatives. Material 
and methods: We synthesized two novel imidazolidine derivatives: (LPSF/PTS10) (Z)-1-
(2-chloro-6-fluorobenzyl)-4-(4-dimethylaminobenzylidene)-5-thioxoimidazolidin-2-one and 
(LPSF/PTS23) (Z)-1-(2-chloro-6-fluoro-benzyl)-5-thioxo-4-(2,4,6-trimethoxy-benzylidene)-
imidazolidin-2-one. The structures of two compounds were determined by spectroscopic 
methods. During the biological assays, parameters such as motility, oviposition, mortality 
and analysis by Scanning Electron Microscopy were performed. Results: LPSF/PTS10 and 
LPSF/PTS23 were considered to be active in the separation of coupled pairs, mortality and 
to decrease the motor activity. In addition, LPSF/PTS23 induced ultrastructural alterations 
in worms, after 24 h of contact, causing extensive erosion over the entire body of the worms. 
Conclusion: The imidazolidine derivatives containing the trimetoxy and benzylidene halogens 
showed promising in vitro schistosomicidal activity.
KEYWORDS: Schistosoma mansoni. Imidazolidines. Ultrastructure.
INTRODUCTION
Parasitic diseases remain obstacles to socioeconomic development in poor 
countries. Schistosomiasis1, an infection caused by trematode worms of the genus 
Schistosoma, is the second most significant parasitic disease in the world after 
malaria. It is a chronic and debilitating disease that continues to threaten millions 
of people, particularly in the rural poor areas of the developing world2. 
The major etiological agent of intestinal schistosomiasis is Schistosoma mansoni, 
and it is estimated that up to 258 million people are infected3. 
The reference drug for the treatment of schistosomiasis is praziquantel (PZQ) 
(2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexa-hydro-4H-pyrazino{2,1-a} isoquinoline-
4-one)4. Recent reports of resistance in some strains raised concern to the world’s 
public health organizations5. In this context, the identification of new and effective 
schistosomicidal compounds is essential6.
At present, various research groups are dedicating efforts to identifying new 
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schistosomicidal agents obtained from natural7,8 and synthetic 
sources9,10. The importance of heterocyclic compounds as 
potential agents against several parasitic diseases, caused by 
protozoa and helminths, is well known11.
The imidazolidines are a broad class of bioactive 
compounds that have also schistosomicidal properties. 
Niridazole, 1-(5-nitrothiazol-2yl) imidazolidin-2-one, a 
drug used during the last century, has been widely applied 
in clinical practice12 and was one of the early treatment 
options to be administered orally13. 
Imidazolidines have antifungal, antimicrobial 
and leishmanicidal14, anti-Trypanosoma cruzi15 and 
schistosomicidal properties16,17. The latter activity of 
imidazolidine derivatives has been demonstrated by in vitro 
studies with adult S. mansoni worms. However, as for PZQ, 
the mechanism of action of the imidazolidines has not yet 
been fully elucidated18,19.
The molecular modification of imidazolidines 
by bioisosteric replacement produces a biological 
response. This study evaluated the biological activity of 
imidazolidine derivatives with different substituent groups 
by determining their in vitro activity against adult worms 
of S. mansoni16-19. 
Two novel imidazolidine compounds (LPSF/
PTS10) (Z)-1-(2-chloro-6-fluorobenzyl)-4-(4-dimethyl 
aminobenzylidene)-5-thioxoimidazolidin-2-one and (LPSF/
PTS23) (Z)-1-(2-chloro-6-fluorobenzyl)-5-thioxo-4-(2,4,6-
trimethoxybenzylidene) imidazolidin-2-one, were tested by 
an in vitro activity evaluation and an ultrastructural analysis 
of the parasite, and by evaluating the cytotoxicity of the 
tested compound on PBMCs.
MATERIALS AND METHODS
Compounds 
The compounds (LPSF/PTS10)-(Z)-1-(2-chloro-
6-fluorobenzyl)-4-(4-dimethyl aminobenzylidene)-
5-thioxoimidazolidin-2-one and (LPSF/PTS23)-
(Z)-1-(2-chloro-6-fluorobenzyl)-5-thioxo-4-(2,4,6-
trimethoxybenzylidene) imidazolidin-2-one were obtained 
from Laboratório de Planejamento e Síntese de Fármacos 
at Universidade Federal de Pernambuco (Brazil) and their 
identities verified by 1H nuclear magnetic resonance of 
hydrogen (1H NMR), infrared (IR) and mass spectroscopy 
(MS).
Scheme 1 displays the synthetic route of the three 
derivatives. The starting reagent was imidazolidine-2,4-
dione (1) which was reacted with 2-chloro-6-fluorobenzyl 
chloride under basic conditions to obtain the intermediate 
3-(2-chloro-6-fluorobenzyl) imidazolidine-2,4-dione 
as previously described (2)20. After that, the reaction of 
3-(2-chloro-6-fluorobenzyl) imidazolidine-2,4-dione 
(2) with Lawesson’s reagent in anhydrous dioxane 
gave the compound 1-(2-chloro-6-fluorobenzyl)-5-
thioxoimidazolidin-2-one (3) according to the protocol 
used by Gouveia et al.21. The reaction mixture was 
heated under reflux for 24 hours. Confirmation of 
the reaction was accomplished by mass spectrometry 
when it was shown that the compound 2 m/z (M + H)+ 
= 243.035 became the compound 3 m/z (M + H)+ = 
259.013 by changing the oxygen atom in the sulfur in 
the structure. Then 2-cyano-3-phenyl-acrylic acid ethyl 
esters derivatives were synthesized through Knoevenagel 
condensation between 4-dimethylaminobenzaldehyde or 
2,4,6-trimethoxybenzaldehyde and ethyl cyanoacetate8. 
A Michael-type addition was then performed by reacting 
the ester derivatives with the intermediate 1-(2-chloro-6-
fluorobenzyl)-5-thioxoimidazolidin-2-one (3) to form the 
final compounds (LPSF/PTS10 and LPSF/PTS23).
Reactions were monitored with analytical thin-
layer chromatography in silica gel 60 F254 plates and 
visualized under UV light (254nm). Melting points were 
determined on a Quimis 340 capillary melting point 
apparatus and were not corrected. Infrared spectra were 
recorded as KBr discs using a BRUKER (IFS66) infrared 
spectrophotometer. 1H NMR spectra were recorded in a 
VMMRS 300 MHz and 400 MHz VARIAN spectrometer 
using tetramethylsilane (TMS) as the internal standard 
and DMSO-d6 as the solvent. 
Chemical shifts (δ, ppm) were assigned according 
to the internal standard signal of TMS in DMSO- d6 
(δ,  ppm). Coupling constants (J) are reported in Hz. 
1H NMR spectra are reported in the following order: 
chemical shift, multiplicity, number and type of proton 
and coupling constant(s). Mass spectra with MALDI-TOF 
Autoflex III (Bruker Daltonics, Billerica, MA, USA). Laser 
Nd: YAG, 355 nm. Freq. laser: 100 Hz. The derivatives 
(LPSF/PTS10; LPSF/PTS23) were isolated as a single 
isomer. X-ray crystallographic studies and 13C NMR have 
shown a preferred Z configuration for 5-benzylidene-
thiazolidinones22-25. 
The presence of the arylidene proton peak in1 H NMR 
for the synthesized derivatives (LPSF/PTS10; LPSF/PTS23) 
confirmed the completion of the nucleophilic addition 
reaction. The compounds were also confirmed by MS data 
in negative mode. 
The IR spectrum of the compound showed characteristic 
peaks of the thiocarbonyl group and arylidene, confirming 
the formation of 5-thioxoimidazolidin-2-one derivatives. 
For the preparation of compounds, equimolar amounts of 
1-(2-chloro-6-fluorobenzyl)-5-thioxoimidazolidin-2-one 
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(3) (200mg) and 2-cyano-3-phenylacrylic acid ethyl ester 
(165 mg) were reacted using absolute ethanol (8 mL) as the 
solvent and morpholine (1 mL) as the catalyst.
The reaction mixture was heated to 50 °C for 8 hours and 
then cooled to room temperature. The solid that precipitated 
out was filtered under vacuum and washed with water and 
absolute ethanol.
Determination of cytotoxicity 
Peripheral blood mononuclear cells were obtained from 
heparinized blood from healthy, nonsmoking donors who 
had not taken any medication for at least 15 days prior to the 
sample collection (10 volunteers), and cells were isolated 
via a standard method of density-gradient centrifugation 
using a Ficoll Hypaque solution (GE Healthcare). Cells 
were counted in a Neubauer chamber, and viability was 
determined by the trypan blue exclusion method. Cells were 
used only when the viability was at last 98%. All the donors 
gave informed consent, and the study was approved by the 
Human Research Ethics Committee of UFPE in the Health 
Sciences Center (CEP/CCS/UFPE N0 483/10 and 57/10). 
Cells were plated in 96-well plates (106 cells/well). After 
24 h, the test compound was added (1, 10 and 100 µM) in 
triplicate wells, the cells were incubated for 48 h and then 
subjected to the MTT assay. 
Cytotoxicity was quantified by the ability of living 
cells to reduce the tetrazolium dye MTT to formazan, 
a purple compound. Measurements were performed by 
using enzyme-linked immunosorbent assay (ELISA) 
kits (eBiosciences, USA, and BD Biosciences, USA) 
according to the manufacturers’ instructions. At the end 
of the incubation period, wells were centrifuged, and the 
medium was replaced by 150 µL of another medium without 
the compound containing MTT (0.5 mg/mL). Three hours 
later the MTT formazan was diluted with 100 µL of 20% 
SDS, and its absorbance was measured at 570 nm in a 
BioTek EL808 reader. Cytotoxic activity was quantified 
as the percentage of reduction in absorbance relative to a 
vehicle treated control. In all the analyzed experiments, the 
vehicle (DMSO 0.1%) treated group presented > 98% of 
viability compared to the control cells without vehicle in 
three independent assays26.
Anti-schistosomal evaluation criteria
Parasites 
S. mansoni (LE strain) worms were maintained in 
Biomphalaria glabrata snails and Swiss webster mice 
hosts at the Schistosomiasis Laboratory of the Department 
of Parasitology, Oswaldo Cruz Foundation, (Pernambuco, 
Brazil). Female mice weighing 28-30g were each exposed 
to around 120 cercariae. 
Mice infection 
Mice were infected by the tail immersion method. 
Briefly, mice were individually placed in a mouse-
holding chamber with their tails outside the chambers. 
After cleaning with dechlorinated tap water, the tail was 
inserted into a vial containing 120 cercariae in 2 mL of 
dechlorinated tap water. Mice were left in contact with 
the infective cercariae for 2 h, and then removed from the 
chamber, and their tails were allowed to dry. After 8 weeks, 
adults S. mansoni worms were recovered from the mice 
Scheme 1 - Reagents and conditions: (i) 2-chloro-6-fluorobenzyl chloride; CH3OH, NaOH, 60º C (ii) Lawesson’s reagent, 90 ºC (iii) 2-cyano-3-(4-dimethylaminephenyl)acrylic acid ethyl ester, CH3CH2OH, 50 ºC; (iv) 2-cyano-3-(2,4,6-trimethoxy-phenyl)acrylic 
acid ethyl ester, CH3CH2OH, 50 ºC.
Matos-Rocha et al.
Rev Inst Med Trop São Paulo. 2017;59:e8Page 4 of 10
by perfusion with RPMI 1640 medium supplemented with 
heparin. The worms were washed in RPMI 1640 medium 
(Gibco) supplemented with 100 µg.mL-1 of streptomycin, 
100 UI.mL-1 of penicillin (Invitrogen), and 25 mM of Hepes. 
Two pairs of adult worms (male and female) were incubated 
in a 24-well culture plate (Techno Plastic Products, TPP) 
containing 2 mL of the same medium supplemented with 
10% heat-inactivated calf serum at 37 ºC in a 5% CO2 
atmosphere, in three independent assays27.
In vitro viability and motility assay with S. mansoni 
For the in vitro test with S. mansoni, LPSF/PTS10 
and LPSF/PTS23 imidazolidine derivatives were the 
compounds rather dissolved in DMSO and the final 
concentration of DMSO in the culture medium was a 
maximum of 1.6% DMSO and used in concentrations 
varying from 5 to 100 µM, which were added to the 
medium containing the worms after a period of 2 h of 
adaptation to the culture medium. In the positive control 
group, the adult worms of S. mansoni were incubated in 
the presence of PZQ, triplicates were carried out for each 
concentration used. 
An inverted microscope and a stereomicroscope 
were used to evaluate the motility and survival of worms 
monitored at 24, 48, 72, 96 and 120 h of incubation. 
Motility and survival of worms were assessed according to 
the criteria scored in a viability scale of 0-3. The scoring 
system was as follows: 3 - complete body movement; 1.5 - 
partial body movement or immobile but alive; and 0 - dead, 
at least three independent assays28. Changes in the pairing 
and egg production were also evaluated using an inverted 
microscope. 
The parasites were kept for 5 days and monitored every 
24 h to evaluate their general condition: motor activity, 
alterations in the tegument, and mortality rate. The control 
worms were treated with 1.6% DMSO in an RPMI 1640 
medium29.
Scanning Electron Microscopy (SEM) 
The worms were incubated for 24 h and, after their 
death, they were washed with sodium cacodylate buffer 
(pH = 7.2), fixed with 2.5% glutaraldehyde (pH = 7.4) 
during 24 h, and then fixed with 1% osmium tetroxide 
for 1 h. The samples were dehydrated by an increasing 
amount of ethanol solution, dried in a critical point dryer, 
then mounted on stubs and coated with gold using a sputter 
coater. The material was examined under a JEOL - 5600 
LV microscope.
RESULTS 
Compound 
(Z ) - 1 - ( 2 - c h l o r o - 6 - f l u o r o b e n z y l ) - 4 - ( 4 -
(dimethylaminobenzylidene)-5-thioxo imidazolidin-2-
one (LPSF/PTS10): The product was an orange solid. 
Formula: C19H17ClFN3OS; M.W.: 389.8742 g/moles; 
Yield: 45%; Melting point: 269-270 ºC; Rf: 0.55 (n-hexane/
AcOEt 6:4); 1H NMR (300MHz, DMSO- d6): δ 3.00 (s, 6H, 
H3C-N); 5.15 (s, 2H, CH2); 6.72 (d, 2H, H-Ar, J= 9.2 Hz); 
7.57 (d, 2H, H-Ar, J= 8.8 Hz); 6.95 (s, 1H, HC=); 7.33 (m, 
2H, CH-Ar, benzyl); 7.17 (t, 1H, CH-Ar, benzyl, J= 8.8 
Hz); 11.00 (s, 1H, NH). IR (KBr, cm-1): 3226.68; 1725.22; 
1588.95; 1531.52. MS [M+H]+: calculated= 390.07; found= 
390.00.
(Z)-1-(2-chloro-6-fluorobenzyl)-5-thioxo-4-(2,4,6-
trimethoxybenzylidene) imidazolidin-2-one (LPSF/
PTS23): The product was an orange solid. Formula: 
C20H18ClFN2O4S; M.W.: 436.8843 g/moles; Yield: 55%; 
Melting point: 152-153º C; Rf: 0.40 (n-hexane/AcOEt 6:4); 
1H NMR (300MHz, DMSO- d6): δ 3.80 9 (s, 6H, OCH3); 
3.83 (s, 3H, OCH3); 5.13 (s, 2H, CH2); 6.26 (s, 2H, CH-
Ar); 6.99 (s, 1H, CH=); 7.18 (t, 1H,CH-benzyl, J= 8.1 Hz); 
7.34 (m, 2H, CH- benzyl); 10.08 (s, 1H, NH). IR (KBr, 
cm-1): 3413.59; 1747.92; 1598.88; 1510.63. MS [M+H]+: 
calculated= 437.06; found= 437.00.
Schistosomicidal activity 
Imidazolidine composites have previously shown action 
against S. mansoni adult worms30-32.
Initially, we performed cell viability tests with the newly 
synthesized imidazolidine derivatives using peripheral 
blood mononuclear cells (PBMCs). Our results show 
that compounds LPSF/PTS10 and LPSF/PTS23, present 
no toxic effects at different concentrations ranging from 
5-100 µM (Table 1).
These compounds were then evaluated for their effects 
on adult schistosomes at a concentration of 5 to 100 µM 
every 24 h for a period of 120 h, and mortality, motility, 
and alterations in the tegument of the worms were observed 
(Table 1). PZQ was used as the reference schistosomicidal 
drug.
In order to evaluate the pairing and egg production by 
adult worms of S. mansoni, the LPSF/PTS10 and LPSF/
PTS23 were tested at concentrations which cause separation 
of coupled adult worms and inhibition in the egg production 
after 120 h of incubation.
LPSF/PTS10 and LPSF/PTS23 all demonstrated 
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lethality against adult worms of S. mansoni, whereas no 
mortality was observed for worms incubated in medium 
alone or in the presence of DMSO. LPSF/PTS10 was more 
effective, causing 100% mortality after 72 h at 20 µM. The 
most effective compound was LPSF/PTS23, which caused 
100% mortality after 24 h at a concentration of 20 µM, and 
some mortality at 5 µM after 120 h incubation.
In these experiments PZQ induced 100% mortality of 
adult worms after 24 h of incubation at all concentrations 
used, down to 5 µM.
Analysis of the effects of the compounds on worm 
motility allowed the detection of their action at sub-lethal 
concentrations (Table 2). During the complete observation 
period (up to 120 h) the negative control group displayed 
peristaltic movements and characteristic waves throughout 
the whole body, with suckers in constant movement and 
occasionally adhering to the bottom of the culture plate 
(score = 3). PZQ caused loss of motility in worms at all 
concentrations used, as early as 24 h after the beginning of 
the incubation leaving them shortened. This effect persisted 
and became stronger over time (score = 0).
After 24 h of exposure to LPSF/PTS23 and 48 h to 
LPSF/PTS10 at a concentration of 100 µM, 100% of the 
worms had lost the movements completely, therefore being 
considered dead (score = 0). 
LPSF/PTS10 at the concentration of 5µM, did not alter 
the motility of S. mansoni during the observation period. 
However, a reduced motility was observed for 50% of 
worms after 24 h of incubation at 20 µM, and 75% were 
dead after 48 h of incubation at this concentration. In the 
case of LPSF/PTS23, its effects on the worms were far 
more radical, and it was therefore not possible to detect 
Table 1 - Cytotoxicity and in vitro effects of LPSF/PTS10 and LPSF/PTS23 against adult worms of Schistosoma mansoni. 
Groups Time (h)
Concentration (µM)
Remarks (worms) Cytotoxicity (µM)a100 40 20 5
Mortality (%)
RPMI 1640
24 - - - -
Paired worms without apparent morphological 
change, presence of eggs. -
48 - - - -
72 - - - -
96 - - - -
120 - - - -
DMSO 1.6%
24 - - - -
Paired worms without apparent morphological 
change, presence of eggs. -
48 - - - -
72 - - - -
96 - - - -
120 - - - -
PZQ
24 100 100 100 100
Not paired, no sucker adherence, absence of 
eggs, tegument morphology altered > 100
48 100 100 100 100
72 100 100 100 100
96 100 100 100 100
120 100 100 100 100
LPSF/PTS10
24 100 - - -
Unpaired, no sucker adherence, absence of 
eggs, tegument morphology altered > 100
48 100 100 - -
72 100 100 100 -
96 100 100 100 -
120 100 100 100 -
LPSF/PTS23
24 100 100 100 -
Unpaired, no sucker adherence, absence of 
eggs, tegument morphology altered > 100
48 100 100 100 -
72 100 100 100 -
96 100 100 100 -
120 100 100 100 25
aCalculated at three concentrations using data obtained from at least three independent experiments, with a SD less than 10% in all cases. The 
highest nontoxic concentration on PBMCs. 
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early effects on motility at the drug concentrations used. At 
5 µM this compound caused a reduction in motility (score 
1.5) in 50% of the worms and 25% were dead.
Observations of worm morphology using SEM showed 
that in the controls, the parasite tegument was observed with 
oral and ventral suckers, and tubercles and spines in normal 
state at 120 h of incubation, (Fig. 1A-B). Severe damage of 
the tegument was observed in worms incubated with PZQ, 
characterized by a contraction and rupture of blisters. The 
emergence of several holes where the blisters had been 
located, and loss of spines has also been observed (Fig. 1C). 
The ultrastructural changes in adult schistosomes caused 
by LPSF/PTS23 were characterized by extensive erosion 
over the entire body of the worms (Fig. 1D); after 48 h, 
multiple bubbles and projections (arrows) emerging from 
the interior of damaged tubercles (Fig. 1E); after 72 h, 
tegument erosion can be visualized at a higher magnification 
(Fig. 1F); After 96 h, some tubercles lack their spines 
(arrow) (Fig. 1G). 
DISCUSSION
Schistosomiasis is a neglected disease that has only one 
drug of choice, PZQ. Because of this, the Special Program 
for Research and Training in Tropical Diseases promoted by 
WHO provides opportunities for studies in the development 
of new anti-Schistosoma drugs and encourages worldwide 
synthesis of new compounds for these neglected disease33-35.
Imidazolidine derivatives have previously been 
investigated for their anti-parasitic activity16-19. The main 
activities assigned to imidazolidines are antibacterial and 
anti-L. amazonensis14, anti-T. cruzi13 and anti-S. mansoni16-19. 
Among the various schistosomicidal compounds that have 
been already tested, imidazolidine derivatives have in vitro 
and in vivo efficacy in several studies, resulting in promising 
results when compared to PZQ, the only drug currently 
available for the treatment of schistosomiasis36,37.
The imidazolidine derivatives used in this study, 
LPSF/PTS10 and LPSF/PTS23 showed no cytotoxicity 
up to 100 µM on PBMCs. LPSF/PTS23 exhibited the best 
schistosomicidal properties in relation to other compounds, 
with 100% mortality within 24 h, at concentrations of 
20-100 µM and marked effects on motility and viability 
after 120 h at 5 µM. These results suggest that the efficacy 
varies according to the substituent in the 4-position of the 
imidazolidine group. The compound LPSF/PTS23 has 
a methoxyl group attached in the 2,4,6-position of the 
imidazoline ring. In a recent study it has been also shown that 
Table 2 - Motility control scores, and worms treated with the derivatives LPSF/PTS10 and LPSF/PTS23, as well as praziquantel 
(PZQ) at different hours post-incubation.
Groups Number of 
worms
Percentage of worms (%) with respect to motility scores after incubationa
24 h 48 h 72 h 96 h 120 h
3.0 1.5 0 3.0 1.5 0 3.0 1.5 0 3.0 1.5 0 3.0 1.5 0
RPMI 1640 100 100 100 100 100
DMSO 1.6% 100 100 100 100 100
PZQ
5 µM 12 100 100 100 100 100
20 µM 12 100 100 100 100 100
40 µM 12 100 100 100 100 100
100 µM 12 100 100 100 100 100
LPSF/PTS10
5 µM 12 100 100 100 100 100
20 µM 12 50 50 25 75 100 100 100
40 µM 12 25 75 100 75 25 100 100
100 µM 12 100 100 100 100 100
LPSF/PTS23
5 µM 12 100 100 100 100 25 50 25
20 µM 12 100 100 100 100 100
40 µM 12 100 100 100 100 100
100 µM 12 100 100 100 100 100
aThe measurement of the mean worm motility was recorded on a scale from 0 to 3, as follows: 3, movement of the whole body; 1.5, movement of 
only one part of the body or immobile but not dead; 0, dead.
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heterocyclic compounds (thiosemicarbazones) containing a 
methoxyl group exhibited higher schistosomicidal activity 
than compounds without this group38.
All adult worm couples were separated into individual 
males and females after incubation with 20, 40 or 100 µM 
of compounds LPSF/PTS10 and LPSF/PTS23. Oviposition 
by adult worms was also not observed at any concentration 
of these imidazolidines (not shown) while in the control 
group (untreated worms) oviposition was observed, and 
the worms remained viable during the entire observation 
period. These same physiological alterations seen here 
were observed in adult worms treated with imidazolidine 
derivatives in other studies conducted by our group (Silva 
et al.32). For example, similar results were achieved by 
Neves et al.30 and Neves et al.31 using 1-(4-chlorobenzyl)-
4-[(4-fluorophenyl)hydrazono]-5-thioxoimidazolidin-
2-one (LPSF/PT11) and 5-(4-fluorobenzylidene-3-(4-
nitrobenzyl)-4-thioxoimidazolidin-2-one (LPSF/RSZ05).
The tegument of S. mansoni is an important structure 
involved in the absorption of nutrients, secretion of some 
products, variety of movements, including rapid shortening 
and extension of the body, typical wavy and peristaltic 
movement along the body axis (anterior and posterior)39. 
Therefore, the worm’s tegument is the critical target for 
imidazolidine derivatives as has been shown in other 
studies16-19.
To test this hypothesis, we first established the 
concentration of LPSF/PTS23 that is capable of altering 
the worm motility, causing death of worms within 120 h 
of exposure in vitro. Based on these criteria, through SEM, 
we observed marked changes in the surface of the tegument 
of S. mansoni adult worms including extensive erosion and 
the emergence of bubbles and projections16,17. Thus, we 
contribute, along with other studies, to the demonstration 
that imidazolidine derivatives induce surface membrane 
damage to adult worms of S. mansoni16-19.
However, despite their effect on the motor activity, the 
exact mechanisms by which LPSF/PTS10 and LPSF/PTS23 
cause mortality in adult worms remain unclear. 
One possible clue is provided by the fact that, some 
imidazolidine derivatives show toxicity to cells16-19. There 
is evidence that these compounds act on cholinergic 
receptors40,41. 
Acetylcholinesterase (AchE) and acetylcholine receptors 
(nAChR) are present particularly on the dorsal surface of 
adult male worms and have a role in nutrient uptake42. 
In particular, glucose uptake in vitro by Schistosoma 
haematobium and Schistosoma bovis adult worms is 
enhanced by the presence of physiological concentrations 
of acetylcholine. Although no such response was shown for 
S. mansoni the role of AChE and nAChR in the uptake of 
other nutrients cannot be ruled out43.
Silva et al.32 evaluated the schistosomicidal potential 
of the imidazolidine derivative 3 (5Z)-3-(4-bromobenzyl)-
5-(4-chlorobenzylidene)-4-thioxoimidazolidin-2-one. 
After 24 hours of incubation at a dose of 100 µg.mL-1, 
adult S. mansoni worms had a significant opening of the 
gynecophoral canal, collapse of the tubercle with erosion 
Figure 1 - a–g SEM images of adult flukes S. mansoni. (a) Adult 
flukes of S. mansoni not exposed to LPSF/PTS23. Parasites 
incubated in maintenance medium for 120 h showing normal 
morphology. (b) GC, gynecophoral channel; OS, oral sucker; 
VS, ventral sucker. Medial and posterior portions; (c) After 24 h, 
extensive erosion was observed over the entire body of the fluke; 
(d) After 48 h, multiple bubbles and projections (solid arrows) 
emerging from the interior of damaged tubercles; (e) After 72 
h, tegument erosion can be visualized at higher magnification; 
(f) After 96 h, some tubercles lack their spines (dashed arrow. 
(g) Damaged tubercles and bubbles present inside the lesion, 
as observed after 120 h of drug exposition. 
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of the tegument and a severe lesion revealing the layer of 
sub tegument tissue. In this case, there was an enormous 
destruction of the sub tegument surface.
Imidazolidine compounds such as (Z)-3-(4-
chlorobenzyl)-5-(4-nitrobenzylidene) imidazolidine-2,4-
dione, (Z)-3-(4-chloro-benzyl)-5-(4-fluorobenzylidene)-
1-methyl-2-thioxoimidazolidin-4-one and (Z)-5-(4-
fluorobenzilidene)-1-methyl-3-(4-phenylbenzyl)-2-
thioxoimidazolidin-4-one induced significant changes in 
the tegumental surface of the body of adult S. mansoni 
worms, causing damage in the tegument with contraction 
of the body and of oral and ventral suckers, disorganization 
and total collapse of the tubercles with loss of spines. Thus, 
the nitro, fluorine and phenyl radicals can justify the good 
activity of the imidazolidine derivatives mentioned above44.
In addition, promising results were also obtained with 
other imidazolidine derivatives presenting chlorine and 
fluorine radicals in their structure, which were also able 
to cause ultrastructural changes in the tegument of adult 
worms of S. mansoni, such as the derivatives 1-benzyl-4-
[(4-chlorophenyl)-hydrazono]-5-thioxoimidazolidin-2-one 
and 1-(4-chlorobenzyl)-4-[(4-fluorophenyl)-hydrazono]-5-
thioxoimidazolidin-2-one11,16,17. 
Furthermore, Neves et al.31 showed disruption to the 
tegument, blisters, spine loss and tissue wrinkling after 
contact with LPSF/PT5 and blisters and swelling of the 
tegument and loss of a few spines in the tubercules after 
incubation with LPSF/PT11. 
Thus, in these cases the presence of nitro, fluorine 
and phenyl radicals could explain the high activity of the 
imidazolidine derivatives45 one explanation may be that 
halogens have the ability to enhance the absorption of the 
derivatives by the cell membranes46. Thus, this may be 
the case in the tegumental surface of the parasite treated 
with the above compounds as well as compounds used in 
the present study which all present the halogens in their 
chemical structures. 
Our study reinforced the use of imidazoline derivatives 
as drug anti-S. mansoni, and identified LPSF/PTS23 as a 
leading candidate for further testing as a potential agent 
against S. mansoni.
CONCLUSION
In conclusion, the imidazoline derivatives which 
presents the trimetoxy and benzylidene halogens showed a 
promising in vitro schistosomicidal activity. This is the first 
time that the in vitro schistosomicidal activity was reported 
for LPSF/PTS10 and LPSF/PTS23. It is now necessary to 
elucidate the mechanisms of action of this compound and 
to evaluate its activity in vivo. 
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